Tozasertib (VX-680, MK-0457)

Catalog No.S1048

Tozasertib (VX-680, MK-0457) Chemical Structure

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 67 Publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Targets
Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150  nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12  hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. [2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 NVzudHdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMECzN|gh|ryP NUfrdZJYW0GQR2LFVi=>
RS4-11 NI\IWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwMEC0NFQh|ryP MmfSV2FPT1KHUh?=
MFH-ino NYPtWVV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\hcY1KSzVyPUCuNFA6QSEQvF2= NGj5NZZUSU6JUlXS
NTERA-S-cl-D1 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTZdll6UUN3ME2wMlAyPDN2IN88US=> M3TLc3NCVkeURWK=
697 M4G5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEK0O|Eh|ryP MUDTRW5IWkWU
NALM-6 NETWbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwMEK1OVIh|ryP MWrTRW5IWkWU
ES8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XnTGlEPTB;MD6wOFYyOyEQvF2= M4LZfXNCVkeURWK=
HUTU-80 NHq5NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjLbHp6UUN3ME2wMlA2Ojl7IN88US=> M3zLcHNCVkeURWK=
MV-4-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMEe3PFIh|ryP M13tbHNCVkeURWK=
MONO-MAC-6 NE\RNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxPXdKSzVyPUCuNFc5PzlizszN MnfIV2FPT1KHUh?=
LC-2-ad NFTQWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID2UYJKSzVyPUCuNFg4QDlizszN MYXTRW5IWkWU
BL-41 M1GwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn4R2dKSzVyPUCuNVA1PDVizszN MmX6V2FPT1KHUh?=
A4-Fuk MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\pNWlEPTB;MD6xNVU3OyEQvF2= M1;MTnNCVkeURWK=
SW954 M1rzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LnVWlEPTB;MD6xNlIzQSEQvF2= M3rkS3NCVkeURWK=
BV-173 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\oNWlEPTB;MD6xNlY1OSEQvF2= NETLTotUSU6JUlXS
TE-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTDflNqUUN3ME2wMlE1QTh{IN88US=> NHPrNVlUSU6JUlXS
SK-UT-1 NWLsPXBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nyfGlEPTB;MD6xOVk3PSEQvF2= MXrTRW5IWkWU
SIG-M5 NX7pOoFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvDTWM2OD1yLkG2O|A4KM7:TR?= NG\Re4VUSU6JUlXS
OCUB-M NXvHUVg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn1TWM2OD1yLkG2PVg{KM7:TR?= NW\hUodIW0GQR2LFVi=>
K052 M2OxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvTSmZKSzVyPUCuNVk1QCEQvF2= MYDTRW5IWkWU
VA-ES-BJ MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMkCwPFYh|ryP MVTTRW5IWkWU
SW982 NHS2eY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmzSVhDUUN3ME2wMlIyOzhizszN M3nwSXNCVkeURWK=
LB647-SCLC MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPKfWJ7UUN3ME2wMlIyPTJ|IN88US=> NX;5WXIxW0GQR2LFVi=>
PSN1 M3HGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjBTWM2OD1yLkKyNFI3KM7:TR?= MXvTRW5IWkWU
BB30-HNC NY\qbFYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnaNYNNUUN3ME2wMlIzPTlzIN88US=> NFLoUGVUSU6JUlXS
ST486 M1jR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;jZ3BKSzVyPUCuNlMxQDdizszN MVTTRW5IWkWU
MOLT-4 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHHe|BUUUN3ME2wMlI{OzN5IN88US=> MX7TRW5IWkWU
EW-16 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;BTWM2OD1yLkKzO|Y5KM7:TR?= NUnZNIdkW0GQR2LFVi=>
KS-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMkO3PFUh|ryP MWPTRW5IWkWU
SR M1TB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfhTWM2OD1yLkK0OVY1KM7:TR?= NH:2eolUSU6JUlXS
KM12 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLXWnhVUUN3ME2wMlI3OzZizszN MkfkV2FPT1KHUh?=
EM-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TkZWlEPTB;MD6yOlY1OSEQvF2= M2G1U3NCVkeURWK=
MEG-01 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4emVKSzVyPUCuNlc5PDlizszN MV\TRW5IWkWU
NB13 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[xOWRKSzVyPUCuNlc6QDRizszN NVLSZ2Q2W0GQR2LFVi=>
RKO NV3oOYZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwM{C4NVMh|ryP NYHIeHNPW0GQR2LFVi=>
CESS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwM{GzNlgh|ryP MmDqV2FPT1KHUh?=
EoL-1-cell NW\GTYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH4ZZdKSzVyPUCuN|M1PTlizszN M1nwVXNCVkeURWK=
DOHH-2 M1iwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXizW4VWUUN3ME2wMlM{PzhzIN88US=> M3PGXnNCVkeURWK=
A388 NYHSZmlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn0W5lKSzVyPUCuN|QxQDZizszN NW\Me|dRW0GQR2LFVi=>
LAMA-84 NX\5Xm5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHTTWM2OD1yLkO1NVc5KM7:TR?= NV3KW|g5W0GQR2LFVi=>
IMR-5 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLmdXJSUUN3ME2wMlM2PTRizszN MYDTRW5IWkWU
KARPAS-422 NHPvR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwM{eyO|Ih|ryP MX7TRW5IWkWU
MRK-nu-1 NWPCeIxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX2TWM2OD1yLkO4NVMh|ryP NIm4NJpUSU6JUlXS
BL-70 MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonQTWM2OD1yLkO4PVc1KM7:TR?= NVyy[GlRW0GQR2LFVi=>
LXF-289 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETTZYZKSzVyPUCuOFA1ODZizszN MVnTRW5IWkWU
RL95-2 M2HFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5WpFiUUN3ME2wMlQxPTZ5IN88US=> M3zrT3NCVkeURWK=
QIMR-WIL NXHkZ|V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNEK2O|Yh|ryP NGXYRmlUSU6JUlXS
K-562 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3GTWM2OD1yLkSzOFczKM7:TR?= MoXNV2FPT1KHUh?=
NCI-H510A NFLRXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwNEO4NlMh|ryP NYO2dIptW0GQR2LFVi=>
NCI-H524 NYDITWFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLLWXRKSzVyPUCuOVEyPDdizszN NIrwZWdUSU6JUlXS
KE-37 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7QTWM2OD1yLkWyNVAzKM7:TR?= M{DvTnNCVkeURWK=
KP-N-YS NWCwTIRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDjUHUxUUN3ME2wMlU1Ozl{IN88US=> NU\USmxHW0GQR2LFVi=>
LS-411N NHzkdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rGZWlEPTB;MD61O|c2OiEQvF2= NFrrcY5USU6JUlXS
CTV-1 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XzU2lEPTB;MD61PFc4OyEQvF2= MXHTRW5IWkWU
NCI-SNU-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfXTWM2OD1yLk[zOVcyKM7:TR?= M1XqfXNCVkeURWK=
HT-144 M1n5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TCfWlEPTB;MD62N|c6QCEQvF2= NEPNWmhUSU6JUlXS
NCI-H187 NXG1O5Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[1N2lEPTB;MD62OFE{KM7:TR?= Mo\lV2FPT1KHUh?=
OCI-AML2 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwNkS0NFMh|ryP MVrTRW5IWkWU
CCRF-CEM NHH3[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNkWzOFYh|ryP MWrTRW5IWkWU
ONS-76 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTvTWM2OD1yLk[2OFU5KM7:TR?= MofDV2FPT1KHUh?=
IST-SL2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j1eGlEPTB;MD63NVk5OiEQvF2= MmHOV2FPT1KHUh?=
NB6 NF7UfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmT6TWM2OD1yLke3NlU1KM7:TR?= NIO3OIZUSU6JUlXS
SK-PN-DW NETEPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwN{mxOEDPxE1? NYXwRmJbW0GQR2LFVi=>
HCC1599 NXTQOpR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT4S|JTUUN3ME2wMlgxQDd2IN88US=> NWnJTlk6W0GQR2LFVi=>
MC116 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfhW4RNUUN3ME2wMlg2ODFzIN88US=> MV\TRW5IWkWU
TE-15 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLzTWM2OD1yLki1NFk5KM7:TR?= NUHIW5pVW0GQR2LFVi=>
HOP-62 NVnSbpFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwOE[zNlkh|ryP MWfTRW5IWkWU
TGBC24TKB M{K2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1iwfWlEPTB;MD64OlM5PSEQvF2= MYHTRW5IWkWU
HCE-4 MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwOEiwOlMh|ryP NUnydJBkW0GQR2LFVi=>
ALL-PO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\FTWM2OD1yLki4NVc2KM7:TR?= M4n1dXNCVkeURWK=
KGN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYToUY95UUN3ME2wMlg6QTl3IN88US=> MnrYV2FPT1KHUh?=
ML-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwOUCyOVkh|ryP MV3TRW5IWkWU
ES4 M2Dwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHwV3RiUUN3ME2wMlkyOTJ6IN88US=> MYfTRW5IWkWU
SF126 M3H1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi0TWM2OD1yLkm0PFE6KM7:TR?= M{fiVHNCVkeURWK=
SK-N-DZ M3zwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXiTWM2OD1yLkm2NVg6KM7:TR?= MWTTRW5IWkWU
HCC1187 NFXUeGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rNOWlEPTB;MT6wNFUxPSEQvF2= NEPqTlRUSU6JUlXS
DU-4475 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfEOmJKSzVyPUGuNFE4PTZizszN M{C5THNCVkeURWK=
NKM-1 Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTFwMEK3O|Uh|ryP MX;TRW5IWkWU
HL-60 NWDzbldiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBdGlEPTB;MT6wOlU4PCEQvF2= NWPQ[482W0GQR2LFVi=>
SBC-1 NHz2ZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTM[m1KSzVyPUGuNVI2PDJizszN Mn;BV2FPT1KHUh?=
TE-10 NEPJZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwMUK5OFYh|ryP MXLTRW5IWkWU
ETK-1 M4\I[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KzfGlEPTB;MT6xN|YyOyEQvF2= Mlq5V2FPT1KHUh?=
HAL-01 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTFwMU[3NFkh|ryP NGP3O5hUSU6JUlXS
BB65-RCC NEi2elVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwMUiwNFUh|ryP NWXKOVFCW0GQR2LFVi=>
EW-1 Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXhTWM2OD1zLkG4OVYzKM7:TR?= NXfLSmF5W0GQR2LFVi=>
SK-NEP-1 M2XZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwMkGxNVEh|ryP MV;TRW5IWkWU
SK-LMS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\lfWlEPTB;MT6yNlIyOiEQvF2= NUHpemI4W0GQR2LFVi=>
DEL NFG3RYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7QXXlKSzVyPUGuNlU3PDNizszN M1rWUHNCVkeURWK=
GT3TKB NVz0cHRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTDTWM2OD1zLkK4NFU4KM7:TR?= M2X5SHNCVkeURWK=
MOLT-16 NGmwUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;5TWM2OD1zLkO1OFA2KM7:TR?= MUPTRW5IWkWU
CMK MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPpVGM6UUN3ME2xMlQzOTF5IN88US=> M2niNnNCVkeURWK=
NB5 NEjIWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwNkSyNlkh|ryP MnTmV2FPT1KHUh?=
NCI-H1963 NIfT[XFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFwN{C1PFMh|ryP NFq5R|lUSU6JUlXS
KURAMOCHI MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlznTWM2OD1zLke4PVEyKM7:TR?= MVPTRW5IWkWU
TE-8 M4PCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH4TWM2OD1zLkiwN|Y5KM7:TR?= NV\reXBjW0GQR2LFVi=>
NCI-H1304 NYf5U291T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwOEOwO|Mh|ryP NVTPO3M2W0GQR2LFVi=>
A101D MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULYcmR3UUN3ME2xMlg4Ozl3IN88US=> MWjTRW5IWkWU
SCLC-21H MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXQSYQ2UUN3ME2xMlk4ODV5IN88US=> NV2xS3pNW0GQR2LFVi=>
GB-1 NFXGR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jRVmlEPTB;Mj6wNVY1PyEQvF2= NX2zNXdHW0GQR2LFVi=>
KARPAS-45 NH\HSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\ZbJRKSzVyPUKuNFI3PTRizszN M4DHNHNCVkeURWK=
ATN-1 NH\m[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjzTWM2OD1{LkCyPFU5KM7:TR?= NX3tcowyW0GQR2LFVi=>
NCI-H720 NEDIPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJwME[yOFQh|ryP NUXHTYVXW0GQR2LFVi=>
RPMI-6666 MkLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfSTWM2OD1{LkG2NlA4KM7:TR?= MoXPV2FPT1KHUh?=
NB17 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDRTWM2OD1{LkK5Nlch|ryP MlzLV2FPT1KHUh?=
IST-SL1 NFvKR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTJwMkm3OlUh|ryP NYjHVHd6W0GQR2LFVi=>
SH-4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDRPGhKSzVyPUKuN|I1PjlizszN MXnTRW5IWkWU
K5 NUTqN3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTNb4pKSzVyPUKuOFA{OTlizszN NW[3dIhnW0GQR2LFVi=>
OVCAR-4 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7MOYtKSzVyPUKuOFYyOyEQvF2= M4TIc3NCVkeURWK=
ACN NFTXVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT6TWM2OD1{LkWwNlE{KM7:TR?= MkDyV2FPT1KHUh?=
TGW MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUGzU|JpUUN3ME2yMlY2QDN{IN88US=> NYSwNIpbW0GQR2LFVi=>
NCI-H2107 NGXXVIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rW[2lEPTB;Mj64N|cyOSEQvF2= NF:ybVJUSU6JUlXS
NCI-H82 NG[2eWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj5ZXlKSzVyPUKuPFM5OzhizszN NUH2bWY1W0GQR2LFVi=>
SK-N-FI MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPpc2lIUUN3ME2yMlg3QDZ6IN88US=> M1XwTXNCVkeURWK=
LB1047-RCC NYDYfXdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPuOnRlUUN3ME2yMlg5OTJ4IN88US=> NXm5V4diW0GQR2LFVi=>
LU-134-A MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSyTWM2OD1{Lki5NlYh|ryP NVTvRVRzW0GQR2LFVi=>
NCI-H209 NXnx[mRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HUdWlEPTB;Mj65NVI2OyEQvF2= NWDF[lFnW0GQR2LFVi=>
NOMO-1 NYO0XW1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD1|LkCyNlc1KM7:TR?= NHnIfY9USU6JUlXS
RH-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwMUeyPVEh|ryP M37ZRnNCVkeURWK=
LOUCY MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HqR2lEPTB;Mz6xPFY6OyEQvF2= MkLuV2FPT1KHUh?=
TE-9 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTNwMk[3N|Yh|ryP NUf4e4xEW0GQR2LFVi=>
PF-382 NIjuR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fYWWlEPTB;Mz6zOVc4QCEQvF2= NHTpdG9USU6JUlXS
RPMI-8402 NFfodWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrqSlVKSzVyPUOuOVg3ODNizszN M2C1cXNCVkeURWK=
HEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXLZXRKSzVyPUOuOlMzKM7:TR?= MXTTRW5IWkWU
NOS-1 NX3E[4IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLMXpZKSzVyPUOuPFQ4PTRizszN Ml\BV2FPT1KHUh?=
ES1 NXqzPItjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkX6TWM2OD1|LkmyNlk{KM7:TR?= M3zsb3NCVkeURWK=
NCI-H2171 NX3Nc4lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLBZmNZUUN3ME2zMlkzPDJ|IN88US=> MYnTRW5IWkWU
NCI-H747 NV7RVFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;Xe2lEPTB;Mz65OFIzOSEQvF2= NXvBcZpqW0GQR2LFVi=>
MHH-NB-11 NVXUfY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV71Z4gzUUN3ME2zMlk2OzF{IN88US=> MlHQV2FPT1KHUh?=
MZ1-PC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1noVWlEPTB;Mz65PVI1KM7:TR?= M2nLR3NCVkeURWK=
MMAC-SF MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jiSWlEPTB;ND6wNlQ3PyEQvF2= MlTvV2FPT1KHUh?=
NMC-G1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwMkK3NlMh|ryP M2PzV3NCVkeURWK=
SW872 M3\OU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTRwM{SzOEDPxE1? MVvTRW5IWkWU
TE-12 NXr3S2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjiTWM2OD12LkW2N|k1KM7:TR?= MmLSV2FPT1KHUh?=
LU-139 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLETWM2OD12Lk[xPFM2KM7:TR?= M2PXN3NCVkeURWK=
HC-1 NGD6ZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnGR5dKUUN3ME20MlY6PDl2IN88US=> M4[yVHNCVkeURWK=
COR-L279 NYm2WWhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorNTWM2OD12Lke1PFkyKM7:TR?= M2mzWnNCVkeURWK=
SF268 M2HEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\TTWM2OD12Lke5PVE3KM7:TR?= MWHTRW5IWkWU
MC-CAR NUDPbWFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTVwME[3OVch|ryP MYDTRW5IWkWU
TK10 M13Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7nVFF1UUN3ME21MlM2PDZ7IN88US=> M1fIW3NCVkeURWK=
TE-1 NE\tN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXaOY1KSzVyPUWuOFkxODRizszN MnHBV2FPT1KHUh?=
NCI-H2126 M1q5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojpTWM2OD13Lk[0OVc1KM7:TR?= NXTxd5lsW0GQR2LFVi=>
Daudi M3W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW2OIVKSzVyPUWuOlkyOiEQvF2= NFi5N2xUSU6JUlXS
NCI-H1648 NYLocWE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rWRWlEPTB;NT64NVQ2PCEQvF2= MWDTRW5IWkWU
OS-RC-2 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOyR3FKSzVyPUWuPVg2QTdizszN MXzTRW5IWkWU
DJM-1 MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTZwM{S2OlYh|ryP NW\KXopVW0GQR2LFVi=>
LS-1034 M4LuUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nnZ2lEPTB;Nj63OVY3KM7:TR?= MV\TRW5IWkWU
NCI-H1581 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDxTWM2OD14Lke4OFA2KM7:TR?= NEK0UGNUSU6JUlXS
UACC-257 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DncGlEPTB;Nz6wOFUyOiEQvF2= NHnGOmhUSU6JUlXS
KM-H2 NVS2WW5ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\4cZNKSzVyPUeuNVg1PTdizszN NUGxSFJoW0GQR2LFVi=>
NCI-H1436 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTdwNkm5N|Ih|ryP M1fPXXNCVkeURWK=
IA-LM NXHIbpduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHBR41CUUN3ME23Mlg2QSEQvF2= MYHTRW5IWkWU
NCI-H526 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\F[WlEPTB;OD6yOVY{PyEQvF2= NX3pOlF6W0GQR2LFVi=>
GCIY NWfBe|JQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRThwM{[5OlUh|ryP NYO1cIppW0GQR2LFVi=>
CP67-MEL NH\LcY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nKSWlEPTB;OD61N|I3KM7:TR?= M3TJSnNCVkeURWK=
KALS-1 M{WwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF75d2JKSzVyPUiuPFM5PTFizszN M{fHN3NCVkeURWK=
NCI-H1770 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRThwOUCyOlUh|ryP M2XsdHNCVkeURWK=
8-MG-BA MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojkTWM2OD17LkOyPFQ1KM7:TR?= MoHoV2FPT1KHUh?=
KY821 NVTrZ5diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fGSmlEPTB;OT63O|Q5PCEQvF2= NUjGSmd3W0GQR2LFVi=>
SNB75 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFyLkC3OkDPxE1? M2DIb3NCVkeURWK=
NCCIT NEn2NZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;1[pBKSzVyPUGxMlA2QDJizszN NGfFTXdUSU6JUlXS
SJSA-1 NV;xe4M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\jNlhZUUN3ME2xNU4zQDlzIN88US=> NHrIVYRUSU6JUlXS
LB373-MEL-D M1LGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTFzLkO4Nlch|ryP NUjRXlh[W0GQR2LFVi=>
TALL-1 NYnaPGt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH2TWM2OD1zMT60NFU5KM7:TR?= NFm3WHJUSU6JUlXS
NB69 M4W3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLEcYpKSzVyPUGxMlc4ODVizszN MnjWV2FPT1KHUh?=
NCI-H1355 NFvYc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomyTWM2OD1zMT65OFI3KM7:TR?= MUPTRW5IWkWU
DMS-153 NWK4UYEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmn3TWM2OD1zMj6wOFI3KM7:TR?= NX[wWW5[W0GQR2LFVi=>
OPM-2 M4\kNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfNZoFKSzVyPUGyMlE2QTZizszN MljKV2FPT1KHUh?=
NB1 NVrsOpZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGH4bWRKSzVyPUGyMlI6KM7:TR?= NHfxVVRUSU6JUlXS
A3-KAW NYnOWHUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLHRZRKSzVyPUGyMlMzOzZizszN MmrmV2FPT1KHUh?=
NCI-H1882 Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq4dJZKSzVyPUGyMlQxPjZizszN MUPTRW5IWkWU
KG-1 MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:4UmlEPTB;MUKuOlU1PSEQvF2= MVjTRW5IWkWU
LC4-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{f6VGlEPTB;MUKuO|cxPiEQvF2= NYXKPIwxW0GQR2LFVi=>
HCE-T NXvwU4RnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZNXc6UUN3ME2xN{4xODR7IN88US=> MoDrV2FPT1KHUh?=
NEC8 NYK3SmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF|LkGwN|gh|ryP M2e1[HNCVkeURWK=
IST-MEL1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7pTWM2OD1zMz61O|g5KM7:TR?= NV3EZ|FTW0GQR2LFVi=>
EW-3 NV3F[ox7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfqNYFKSzVyPUGzMlc1ODJizszN MXTTRW5IWkWU
CTB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLSTWM2OD1zND6wN|I6KM7:TR?= MXnTRW5IWkWU
LS-123 NGPQUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjhfY9nUUN3ME2xOE4yPTh6IN88US=> MU\TRW5IWkWU
NCI-H1417 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGniUpRKSzVyPUG0MlMxPTJizszN NXPkZ2hOW0GQR2LFVi=>
MZ7-mel NWrMbINDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTQTWM2OD1zND60OFM{KM7:TR?= NGXK[HNUSU6JUlXS
JiyoyeP-2003 NYq2dnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnJ[llKSzVyPUG1MlY{OjZizszN M2DrVnNCVkeURWK=
ES6 NFHK[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLlcIRMUUN3ME2xOk4zOzZzIN88US=> Ml:5V2FPT1KHUh?=
HH M2nnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTCTWM2OD1zNz6xPVY{KM7:TR?= NVLa[Y5UW0GQR2LFVi=>
SF539 NGq3NmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX3[HpKSzVyPUG3Mlk6OjJizszN NEmyTmNUSU6JUlXS
Calu-6 NFyyfoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX0WopUUUN3ME2xPU4zOzlizszN M1fuNXNCVkeURWK=
SK-MM-2 MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF7LkW1OUDPxE1? NFq0UpJUSU6JUlXS
IST-MES1 NFzvOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjTWM2OD1zOT62OlY{KM7:TR?= NEnjfmhUSU6JUlXS
GI-ME-N MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTF7LkiyNlch|ryP M2nmcXNCVkeURWK=
CAL-148 M2HIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nQNGlEPTB;MkCuPVk{PCEQvF2= NF7PeGpUSU6JUlXS
EVSA-T MmLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorTTWM2OD1{MT6xOFk6KM7:TR?= NEP2eJNUSU6JUlXS
LP-1 MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3faRmlEPTB;MkGuN|Q{OiEQvF2= M{XEeHNCVkeURWK=
BOKU M1rke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLlTWM2OD1{MT60OVM{KM7:TR?= MX3TRW5IWkWU
KLE Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ{LkG5NFMh|ryP MnnBV2FPT1KHUh?=
LB831-BLC NYnnTWd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\kfoRKSzVyPUK1MlE2OjZizszN NXf5dlJLW0GQR2LFVi=>
NCI-H889 NEXCZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfJZ|RKSzVyPUK1MlE6OzFizszN MVjTRW5IWkWU
REH MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7z[pE3UUN3ME2yOU41PjdzIN88US=> M4TyVHNCVkeURWK=
KP-N-RT-BM-1 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJ3LkS3OVIh|ryP NHfEW|FUSU6JUlXS
MPP-89 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfN[VFvUUN3ME2yOU42OzF2IN88US=> NY\xRol5W0GQR2LFVi=>
no-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HPZWlEPTB;MkWuO|Q4KM7:TR?= NUf1PWFqW0GQR2LFVi=>
NCI-H748 NFTWflZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXIT3dPUUN3ME2yOU44PjJ5IN88US=> NGfaRpJUSU6JUlXS
LB2518-MEL NEfEeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnBZpdKSzVyPUK3MlE4PzNizszN NWHi[pVlW0GQR2LFVi=>
TGBC1TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDhR3RtUUN3ME2yO{42PTh3IN88US=> NVuwWYxsW0GQR2LFVi=>
MHH-PREB-1 M4TiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TZdWlEPTB;MkiuNFc{PCEQvF2= M{jt[XNCVkeURWK=
MZ2-MEL NGfIZ4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnnT5JKSzVyPUK4MlYyPDNizszN MVnTRW5IWkWU
U-266 NHXhO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTJ6Lk[zOlYh|ryP MVzTRW5IWkWU
SNU-C1 M{fxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TTSmlEPTB;MkiuPVQ{KM7:TR?= NYS1dVlwW0GQR2LFVi=>
SW962 NVz0O41TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIm0TmtKSzVyPUOwMlI4PDdizszN MmnwV2FPT1KHUh?=
Raji M2DjSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BTWM2OD1|MD61OVkzKM7:TR?= NWO0fYxYW0GQR2LFVi=>
KNS-42 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HxOWlEPTB;M{CuPFk2PiEQvF2= NVq1dVBXW0GQR2LFVi=>
LB996-RCC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXJTWM2OD1|MT6xO|AzKM7:TR?= MXnTRW5IWkWU
CHP-126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLzTWM2OD1|MT6xPVg1KM7:TR?= NXO3VoN4W0GQR2LFVi=>
RXF393 NGLKT4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLPTWM2OD1|Mj60PVch|ryP NXL4WYdzW0GQR2LFVi=>
COLO-684 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3NTWM2OD1|Mj62OFM5KM7:TR?= M3PofHNCVkeURWK=
A704 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nTemlEPTB;M{OuOVU{QCEQvF2= M2XhbXNCVkeURWK=
A253 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXWVXFHUUN3ME2zN{42QDV{IN88US=> NWq1dYk2W0GQR2LFVi=>
KNS-81-FD NY\jNJVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37sV2lEPTB;M{SuOVQ2PiEQvF2= Ml3qV2FPT1KHUh?=
TE-441-T NWSydnlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDMTWM2OD1|ND62N|cyKM7:TR?= NWraVnRoW0GQR2LFVi=>
HCC2157 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nXR2lEPTB;M{WuOFYyQSEQvF2= M{fKbHNCVkeURWK=
ES3 NELIU2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXFTWM2OD1|Nj62O|Uh|ryP MnzWV2FPT1KHUh?=
NCI-H1155 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN5LkixOUDPxE1? NUP0XZpuW0GQR2LFVi=>
SNU-C2B M4fzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzaUWlKSzVyPUO4MlE3PTRizszN MX\TRW5IWkWU
JAR NUXGdFhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrrTWM2OD1|OD6yOFQ6KM7:TR?= NIPyc29USU6JUlXS
GDM-1 M{C0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfjTWM2OD1|OD65NVE3KM7:TR?= Mor6V2FPT1KHUh?=
KU812 M2DXXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGzbnFkUUN3ME20NU42ODdizszN MW\TRW5IWkWU
BC-1 M135Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3frbGlEPTB;NEKuOlc{OSEQvF2= NWfpZ4pSW0GQR2LFVi=>
GI-1 NWPiVIdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPBbmNDUUN3ME20Nk46OTl{IN88US=> Mlq2V2FPT1KHUh?=
NCI-H1694 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR2Lkm0O|Ih|ryP MYXTRW5IWkWU
DG-75 M1rYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3vVFJlUUN3ME20OU4yPTd5IN88US=> M{nkTnNCVkeURWK=
COR-L88 NFXvWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoH0TWM2OD12NT6yO|c5KM7:TR?= MYnTRW5IWkWU
LS-513 M2HCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjSWG1[UUN3ME20OU46OTV4IN88US=> NHvpdVNUSU6JUlXS
HD-MY-Z M4DkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzYbZB2UUN3ME20Ok41PjF{IN88US=> NX\LNmNGW0GQR2LFVi=>
L-363 M1\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV72Z2pTUUN3ME20Ok45QDFizszN MYHTRW5IWkWU
TE-6 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjPTmw4UUN3ME20PE41PDZizszN MVfTRW5IWkWU
NCI-H345 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXwTWM2OD12OD60Olgh|ryP M4DBXXNCVkeURWK=
TE-5 NV3ycVRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfIUopZUUN3ME20PU44OTF6IN88US=> NF7QWJFUSU6JUlXS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DLK / p-MKK7 / MKK7 / p-JNK / JNK ; 

PubMed: 23431148     


Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. 

p-AURKA / AURKA / Survivin ; 

PubMed: 28218735     


BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. 

YAP; 

PubMed: 31160567     


Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. 

p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 21600017     


NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.

23431148 28218735 31160567 21600017
Immunofluorescence
α-tubulin / Aurora-A ; 

PubMed: 21600017     


The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.

21600017
Growth inhibition assay
Cell viability; 

PubMed: 21600017     


VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, *p < 0.05, **p < 0.01, compared to control.

21600017
In vivo VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. [1]

Protocol

Kinase Assay:

[3]

- Collapse

Kinase inhibition assays:

The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K i = IC50 / (1 + [S]/Kd), where [S] = [ATP] = 2.2 mM, and Kd (of ATP to Abl) = 70 μM. These values are calculated assuming a Kd (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research:

[2]

- Collapse
  • Cell lines: CAL-62 cells
  • Concentrations: 5-500 nM
  • Incubation Time: 4 days
  • Method:

    The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500  nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500  nM). The cells are pulse labeled with 30  mM BrdU for 2  hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells
  • Formulation: 50% PEG300 in 50 mM phosphate buffer
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.59
Formula

C23H28N8OS

CAS No. 639089-54-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) supplier | purchase Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) cost | Tozasertib (VX-680, MK-0457) manufacturer | order Tozasertib (VX-680, MK-0457) | Tozasertib (VX-680, MK-0457) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID